Influenza is a disease that has historically had serious problems with prevention and treatment. Currently, the flu vaccine is the only vaccine that requires annual administration. This is due to the inherent characteristics of the influenza virus, which exhibits strong antigenic drift and constantly mutates. The virus may look different every year, leaving patients no longer protected. Subsequently, influenza can have a serious health burden; for example, in the United States, there were 810,000 hospital admissions and 61,000 deaths from influenza during the 2017-2018 flu season.
FDA representatives have approved lumateperone intracellular therapy (Caplyta) for the treatment of adult schizophrenia, according to the company. It is expected that the drug will be launched in 2020.
Patients with rheumatoid arthritis (RA), whose disease occurred at an older age, and patients whose disease appeared at an earlier age, had similar improvements in clinical disease 48 weeks after starting the use of Antirheumatic drugs that modify the biological disease, according to a poster presented at the American College. rheumatology / annual meeting of the Association of rheumatologists.
Officials with the FDA approved voxelotor pills (Oxbryta, Global Blood Therapeutics [GBT]) to treat (SCD) in adults and children ages 12 and older, according to a press release.
Treatment with evolocumab (Repatha, Amgen) has shown comparative benefit in high-risk patients who have had recent myocardial infarction (MI), according to a new analysis presented at the annual meeting of the American Association of Cardiology in Philadelphia, PA.